Jack Hoppin
Chief Executive Officer Ratio Therapeutics
Seminars
Wednesday 24th February 2027
Roundtable Discussion: Defining the RLT Target Validation Package to Determine When the Biology Strong Enough to Progress to the Clinic
12:00 pm
- Validating tumor-to-healthy expression, prevalence, & heterogeneity to confirm the target is sufficiently selective and consistent to progress
- Assessing accessibility, internalization, replenishment, & density to prove the target can support meaningful radionuclide delivery
- Defining the minimum in vitro, in vivo & imaging evidence to make earlier, higherconfidence target go/no-go decisions
